Business Context and Reporting Period
This Form 8-K was filed by Nuvilex, Inc. (noted as Pharmacyte Biotech, Inc. in metadata) on February 14, 2014. The filing reports the entry into a material definitive agreement and the unregistered sale of equity securities. The company is a Nevada corporation headquartered in Silver Spring, Maryland.
Key Financial Metrics and Transaction Details
- Total Facility Size: $27,000,000 purchase agreement for common stock.
- Initial Investment: $2,000,000 received immediately for 8,000,000 shares of common stock.
- Remaining Capacity: Up to $25,000,000 available for future purchases over a 30-month period.
- Commitment Shares: 5,062,500 shares issued immediately as consideration for the commitment; an additional 5,062,500 shares issuable pro rata or if registration is not effective within 270 days.
- Pricing Mechanism: Future share prices based on prevailing market prices (subject to discounts); no upper price limit; a floor price exists below which the investor is not obligated to purchase.
- Counterparty: Lincoln Park Capital Fund, LLC.
Material Changes Versus Prior Period
This filing represents a discrete event rather than a periodic financial update. The material change is the establishment of a new equity financing facility. Unlike prior periods, the company now has a committed source of capital up to $27 million, subject to market conditions and a registration statement becoming effective.
Guidance, Outlook, and Risks
- Management Discretion: The company controls the timing and amount of future sales to Lincoln Park. Actual sales depend on market conditions and the company's funding needs.
- Termination Rights: The company may terminate the agreement at any time without monetary cost or penalty.
- Registration Requirement: Future sales are contingent on the SEC declaring a registration statement effective. If not effective within 270 days, additional commitment shares are issued.
- Financial Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels.
Investor Verification Checklist
- Verify the effectiveness of the registration statement required for the $25,000,000 drawdown.
- Confirm the specific "floor price" and discount terms detailed in the attached Purchase Agreement (Exhibit 10.1).
- Monitor the issuance of the 5,062,500 commitment shares and the potential issuance of the additional 5,062,500 shares.
- Review the press release (Exhibit 99.1) for any additional operational context not included in the 8-K.